首页 | 本学科首页   官方微博 | 高级检索  
检索        

干扰素α-2b治疗HBeAg阳性慢性乙肝疗效及其预测因素分析
引用本文:李海军,杨新英,康富标,李东,孙殿兴.干扰素α-2b治疗HBeAg阳性慢性乙肝疗效及其预测因素分析[J].解放军医学高等专科学校学报,2011(2):230-232.
作者姓名:李海军  杨新英  康富标  李东  孙殿兴
作者单位:解放军白求恩国际和平医院传染肝病科一病区,河北石家庄050082
摘    要:目的观察普通干扰素治疗HBeAg阳性慢性乙肝的临床效果及其预测因素。方法选择近年收治的未应用过抗病毒药物的HBeAg阳性慢性乙肝患者,给予普通干扰素抗病毒治疗48周,随访24周,观察其临床疗效及其预测因素。结果持续应答率为23.28%,HBeAg血清转换率为34.48%,持续应答组HBeAg血清转换率为63.04%。性别、是否母婴传播与抗病毒效果无关,基线HBV-DNA、ALT、AST、TBIL、GGT水平与抗病毒效果相关。基线HBV-DNA、ALT、GGT水平可以作为普通干扰素治疗HBeAg阳性慢性乙肝患者抗病毒效果的预测因素。结论普通干扰素治疗HBeAg阳性慢性乙肝疗效确切。持续应答的患者能够获得较高的HBeAg血清转换率。根据患者基线HBV-DNA水平及肝功能情况选择合适的患者是提高应答率的关键。

关 键 词:干扰素  慢性乙型病毒性肝炎  预测因素

Analysis on efficacy and predictive factor of interferon alpha-2b in treatment of HBeAg-positive chronic hepatitis B
Li Hai-jun,Yang Xin-ying,Kang Fu-biao,Li Dong,Sun Dian-xing.Analysis on efficacy and predictive factor of interferon alpha-2b in treatment of HBeAg-positive chronic hepatitis B[J].Clinical Journal of Medical Officer,2011(2):230-232.
Authors:Li Hai-jun  Yang Xin-ying  Kang Fu-biao  Li Dong  Sun Dian-xing
Institution:(Department of Infectious Diseases and Liver Disease,Bethune International Peace Hospital.Shijiazhuang Hebei 050082.China)
Abstract:Objective To evaluate the efficacy and the predictive factor in the treatment of HBeAg-positive chronic hepatitis B with ordinary interferon alpha-2b.Methods Select patients with HBeAg-positive chronic hepatitis B of our hospitals in recent years has not been admitted to the application of antiviral drugs,giving interferon alpha-2b 48 weeks of antiviral treatment,follow-up 24 weeks,to evaluate the efficacy and the predictive factor.Results In this study,the sustained response rate was 23.28%,HBeAg serum conversion rate was 34.48%,and sustained response group HBeAg serum conversion rate was 63.04%.Gender,whether they are mother-to-child transmission are irrelevant with antiviral effect.Baseline HBV-DNA,ALT,AST,TBIL,GGT level are related to antiviral effect.Baseline HBV-DNA,ALT,GGT level can be used as predictors of antiviral effect of ordinary interferon alpha-2b to treat HBeAg-positive chronic hepatitis B.Conclusion Ordinary interferon could be used as a safe and effective drug in the treatment of HBeAg-positive chronic hepatitis B.Sustained response can get higher HBeAg serum conversion rate.According baseline HBV-DNA level and liver function choose the right patient is the key to improving response rates.
Keywords:interferon  chronic hepatitis B  predictive factor
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号